Assignee
BEYONDSPRING PHARMACEUTICALS INC
US·20 granted patents·14 pending applications·131 citations·filing 2016–2025
Top patents by PatentIndex Score
34 records- 0197US10550104B2Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Granted Feb 4, 2020·14 cites·20 claims
- 0296US11045467B2Method of treating cancer associated with a RAS mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2020·Granted Jun 29, 2021·7 cites·20 claims
- 0396US10357491B2Method of treating a brain tumorBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Granted Jul 23, 2019·13 cites·20 claims
- 0496US10238650B2Method of treating cancer associated with a RAS mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2016·Granted Mar 26, 2019·18 cites·24 claims
- 0596US10155748B2Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2016·Granted Dec 18, 2018·15 cites·9 claims
- 0695US11254657B2Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2020·Granted Feb 22, 2022·5 cites·16 claims
- 0794US12024501B2Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Granted Jul 2, 2024·4 cites·20 claims
- 0893US11918574B2Method of treating cancer associated with a RAS mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2021·Granted Mar 5, 2024·2 cites·20 claims
- 0993US10668063B2Method of treating cancer associated with a RAS mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Granted Jun 2, 2020·12 cites·21 claims
- 1093US10076518B2Method of treating a brain tumorBEYONDSPRING PHARMACEUTICALS INC·Filed 2016·Granted Sep 18, 2018·15 cites·19 claims
- 1192US11229642B2Composition and method for reducing neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2017·Granted Jan 25, 2022·6 cites·25 claims
- 1292US10912748B2Compositions containing tucaresol or its analogsBEYONDSPRING PHARMACEUTICALS INC·Filed 2017·Granted Feb 9, 2021·8 cites·18 claims
- 1391US11857522B2Compositions containing tucaresol or its analogsBEYONDSPRING PHARMACEUTICALS INC·Filed 2021·Granted Jan 2, 2024·2 cites·26 claims
- 1488US11786523B2Composition and method for reducing thrombocytopeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Granted Oct 17, 2023·3 cites·31 claims
- 1586US11400086B2Method of reducing chemotherapy-induced neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Granted Aug 2, 2022·5 cites·19 claims
- 1682US2024425485A1Plinabulin compositionsBEYONDSPRING PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1781US11633393B2Tubulin binding compounds and therapeutic use thereofBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Granted Apr 25, 2023·2 cites·2 claims
- 1880US12377094B2Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapiesBEYONDSPRING PHARMACEUTICALS INC·Filed 2024·Granted Aug 5, 2025·0 cites·22 claims
- 1975US12458638B2Method of stimulating neutrophil survival and reducing neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Granted Nov 4, 2025·0 cites·21 claims
- 2071US12458639B2Tubulin binding compounds and therapeutic use thereofBEYONDSPRING PHARMACEUTICALS INC·Filed 2023·Granted Nov 4, 2025·0 cites·2 claims
- 2168US2025375440A1Composition and method of treating cancer associated with egfr mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2267US12433886B2Composition and method for reducing neutropeniaBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Granted Oct 7, 2025·0 cites·19 claims
- 2365US2024197723A1Therapeutic compositions and methods for treating tumorsBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2463US2025152473A1Stable plinabulin formulations and methods of their preparation and useBEYONDSPRING PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2563US2025073230A1Use of plinabulin in combination with immune checkpoint inhibitorsBEYONDSPRING PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2658US2024408082A1Methods for treating cancers and tumorsBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2755US2023181605A1Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicityBEYONDSPRING PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2853US2024368126A1Impurity in plinabulin or preparation thereof, and use thereofBEYONDSPRING PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2952US2021161888A1Composition and method of treating cancer associated with egfr mutationBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3052US2024299377A1Methods and compositions for treating iron disordersBEYONDSPRING PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3151US2021177952A1Method and composition for stimulating immune responseBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3250US2022387365A1Tucaresol derivatives and uses thereofBEYONDSPRING PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3344US2021030843A1Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agentBEYONDSPRING PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3443US2020129504A1Compositions of plinabulin and use thereofBEYONDSPRING PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BEYONDSPRING PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →